Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy

References

• Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007; 75:770-87; PMID:17999740; http://dx.doi.org/10.1111/j.1432-0436.2007.00238.x
   PubMed Web of Science ®Google Scholar
• Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000; 21:105-15; PMID:10686540; http://dx.doi.org/10.1159/000030116
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 Suppl 4:S9-15; PMID:11597399; http://dx.doi.org/10.1016/S0959-8049(01)00231-3
   PubMed Web of Science ®Google Scholar
• Wang X, Zhu J, Zhao P, Jiao Y, Xu N, Grabinski T, Liu C, Miranti CK, Fu T, Cao BB. In vitro efficacy of immuno-chemotherapy with anti-EGFR human Fab-Taxol conjugate on A431 epidermoid carcinoma cells. Cancer Biol Ther 2007; 6:980-7; PMID:17534145; http://dx.doi.org/10.4161/cbt.6.6.4197
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11; PMID:15837620; http://dx.doi.org/10.1016/j.ccr.2005.03.003
   PubMed Web of Science ®Google Scholar
• Iida M, Brand TM, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia 2013; 15:1196-206; PMID:24204198; http://dx.doi.org/10.1593/neo.131584
   PubMed Web of Science ®Google Scholar
• Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6:803-12; PMID:16990857; http://dx.doi.org/10.1038/nrc1970
   PubMed Web of Science ®Google Scholar
• Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4:107-19; PMID:19452131; http://dx.doi.org/10.1007/s11523-009-0114-0
   PubMed Web of Science ®Google Scholar
• Mascia F, Mariani V, Girolomoni G, Pastore S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163:303-12; PMID:12819035; http://dx.doi.org/10.1016/S0002-9440(10)63654-1
   PubMed Web of Science ®Google Scholar
• Lichtenberger BM, Gerber PA, Holcmann M, Buhren BA, Amberg N, Smolle V, Schrumpf H, Boelke E, Ansari P, Mackenzie C, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 2013; 5:199ra11; PMID:23966300; http://dx.doi.org/10.1126/scitranslmed.3005886
   PubMed Web of Science ®Google Scholar
• Sandersjoo L, Jonsson A, Lofblom J. A new prodrug form of Affibody molecules (pro-Affibody) is selectively activated by cancer-associated proteases. Cell Mol Life Sci 2015; 72:1405-15; PMID:25287047; http://dx.doi.org/10.1007/s00018-014-1751-8
   PubMed Web of Science ®Google Scholar
• Baumann A, Flagella K, Forster R, de Haan L, Kronenberg S, Locher M, Richter WF, Theil FP, Todd M. New challenges and opportunities in nonclinical safety testing of biologics. Regul Toxicol Pharmacol 2014; 69:226-33; PMID:24755365; http://dx.doi.org/10.1016/j.yrtph.2014.04.005
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EE, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ, et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med 2013; 5:207ra144; PMID:24132639; http://dx.doi.org/10.1126/scitranslmed.3006682
   PubMed Web of Science ®Google Scholar
• de Goeij BE, Satijn D, Freitag CM, Wubbolts R, Bleeker WK, Khasanov A, Zhu T, Chen G, Miao D, van Berkel PH, et al. High turnover of Tissue Factor enables efficient intracellular delivery of antibody-drug conjugates. Mol Cancer Ther 2015; 14(5):1130-40; PMID:25724665; http://dx.doi.org/10.1158/1535-7163
   PubMed Web of Science ®Google Scholar
• Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010; 14:529-37; PMID:20643572; http://dx.doi.org/10.1016/j.cbpa.2010.06.170
   PubMed Web of Science ®Google Scholar
• Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des 2013; 81:113-21; PMID:23253133; http://dx.doi.org/10.1111/cbdd.12085
   PubMed Web of Science ®Google Scholar
• Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci U S A 1996; 93:8618-23; PMID:8710920; http://dx.doi.org/10.1073/pnas.93.16.8618
   PubMed Web of Science ®Google Scholar
• Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J, Raab H, Januario T, Go M, Lau J, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 2010; 24:1566-73; PMID:20596033; http://dx.doi.org/10.1038/leu.2010.141
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2011; 29:351-4; PMID:21172881; http://dx.doi.org/10.1200/JCO.2010.31.6679
   PubMed Web of Science ®Google Scholar
• Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, Erickson H, Kovtun Y, Chari R, Jordan MA. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 2010; 9:2700-13; PMID:20937595; http://dx.doi.org/10.1158/1535-7163.MCT-10-0645
   PubMed Web of Science ®Google Scholar
• Lopus M. Antibody-DM1 conjugates as cancer therapeutics. Cancer Lett 2011; 307:113-8; PMID:21481526; http://dx.doi.org/10.1016/j.canlet.2011.03.017
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011; 17:6437-47; PMID:22003071; http://dx.doi.org/10.1158/1078-0432.CCR-11-0762
   PubMed Web of Science ®Google Scholar
• Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med 2009; 50:1116-23; PMID:19525473; http://dx.doi.org/10.2967/jnumed.109.061820
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70:588-97; PMID:20068188; http://dx.doi.org/10.1158/0008-5472.CAN-09-1417
   PubMed Web of Science ®Google Scholar
• Yang Y, Guo Q, Xia M, Li Y, Peng X, Liu T, Tong X, Xu J, Guo H, Qian W, et al. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency. MAbs 2015; 7:440-50; PMID:25679409; http://dx.doi.org/10.1080/19420862.2015.1008352
   PubMed Web of Science ®Google Scholar
• Feng L, Yao HP, Wang W, Zhou YQ, Zhou J, Zhang R, Wang MH. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy. Clin Cancer Res 2014; 20:6045-58; PMID:25294907; http://dx.doi.org/10.1158/1078-0432.CCR-14-0898
   PubMed Web of Science ®Google Scholar
• Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68:9280-90; PMID:19010901; http://dx.doi.org/10.1158/0008-5472.CAN-08-1776
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010; 70:2528-37; PMID:20197459; http://dx.doi.org/10.1158/0008-5472.CAN-09-3546
   PubMed Web of Science ®Google Scholar
• Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28:2698-704; PMID:20421541; http://dx.doi.org/10.1200/JCO.2009.26.2071
   PubMed Web of Science ®Google Scholar
• Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012; 18:221-3; PMID:22270724; http://dx.doi.org/10.1038/nm.2609
   PubMed Web of Science ®Google Scholar
• Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PY, Lum LG. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res 2006; 12:183-90; PMID:16397041; http://dx.doi.org/10.1158/1078-0432.CCR-05-1855
   PubMed Web of Science ®Google Scholar
• Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, et al. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer. Cancer Sci 2013; 104:1346-52; PMID:23863134; http://dx.doi.org/10.1111/cas.12237
   PubMed Web of Science ®Google Scholar
• Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung MC. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008; 13:385-93; PMID:18455122; http://dx.doi.org/10.1016/j.ccr.2008.03.015
   PubMed Web of Science ®Google Scholar
• Golubovskaya V, Beviglia L, Xu LH, Earp HS, 3rd, Craven R, Cance W. Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells. J Biol Chem 2002; 277:38978-87; PMID:12167618; http://dx.doi.org/10.1074/jbc.M205002200
   PubMed Web of Science ®Google Scholar
• Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 2011; 13:R46; PMID:21510863; http://dx.doi.org/10.1186/bcr2868
   PubMed Web of Science ®Google Scholar
• Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007; 25:1134-43; PMID:17921999; http://dx.doi.org/10.1038/nbt1337
   PubMed Web of Science ®Google Scholar
• Khan MH, Alam M, Yoo S. Epidermal growth factor receptor inhibitors in the treatment of nonmelanoma skin cancers. Dermatol Surg 2011; 37:1199-209; PMID:21615602; http://dx.doi.org/10.1111/j.1524-4725.2011.02038.x
   PubMed Web of Science ®Google Scholar
• Liu G, Shuman MA, Cohen RL. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 1995; 60:501-6; PMID:7829264; http://dx.doi.org/10.1002/ijc.2910600413
   PubMed Web of Science ®Google Scholar
• Corti A, Nolli ML, Soffientini A, Cassani G. Purification and characterization of single-chain urokinase-type plasminogen activator (pro-urokinase) from human A431 cells. Thromb Haemost 1986; 56:219-24; PMID:3101222
   PubMed Web of Science ®Google Scholar
• Safavy A, Bonner JA, Waksal HW, Buchsbaum DJ, Gillespie GY, Khazaeli MB, Arani R, Chen DT, Carpenter M, Raisch KP. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem 2003; 14:302-10; PMID:12643740; http://dx.doi.org/10.1021/bc020033z
   PubMed Web of Science ®Google Scholar
• Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425-33; PMID:16012181; http://dx.doi.org/10.1093/annonc/mdi279
   PubMed Web of Science ®Google Scholar
• Weidle UH, Tiefenthaler G, Georges G. Proteases as activators for cytotoxic prodrugs in antitumor therapy. Cancer Genomics Proteomics 2014; 11:67-79; PMID:24709544
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, Trueblood ES, Meininger D, Arora T, Twomey B, et al. AMG 595, an anti-EGFRvIII Antibody Drug Conjugate, Induces Potent Anti-Tumor Activity Against EGFRvIII Expressing Glioblastoma. Mol Cancer Ther 2015; 14(7):1614-24; PMID:25931519 doi: http://dx.doi.org/10.1158/1535-7163
   PubMed Web of Science ®Google Scholar
• Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009; 1:41-8; PMID:20046573; http://dx.doi.org/10.4161/mabs.1.1.7509
   PubMed Web of Science ®Google Scholar
• Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res 2011; 17:5935-44; PMID:21791633; http://dx.doi.org/10.1158/1078-0432.CCR-11-0370
   PubMed Web of Science ®Google Scholar
• Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 2010; 16:4769-78; PMID:20805300; http://dx.doi.org/10.1158/1078-0432.CCR-10-0987
   PubMed Web of Science ®Google Scholar
• Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer DL, Doronina SO, Siegall CB, Francisco JA, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. Clin Cancer Res 2004; 10:7842-51; PMID:15585616; http://dx.doi.org/10.1158/1078-0432.CCR-04-1028
   PubMed Web of Science ®Google Scholar